@FierceMedDev: ICYMI yesterday: Roche launches point-of-care, PCR molecular diagnostic system from $450M deal for iQuum. Report | Follow @FierceMedDev
@EmilyWFierce: Philips to acquire Volcano for $1.2B to expand in image-guided therapy. Report from Reuters | Follow @EmilyWFierce
> Mayo Clinic will be collaborating with DermSpectra to test the latter's Total Body Digital Skin Imaging System, to analyze patient and dermatologists' perceptions of the impact of digital skin imaging in skin documentation and medical decision making. Release
> Bovie Medical, maker of medical devices and supplies, received FDA 510(k) approval for the Bovie Ultimate, a high frequency electrosurgical generator that can be used to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. Release
> Medical workers can significantly reduce exposure to radiation during cardiac-catheterization procuders by using a real-time radiation monitor that alerts the user to radiation levels through audible beeps. Release
> The FDA passed an allowance for EnLite Neonatal TREC Kit, the first screening test on newborns, to be marketed to check for Severe Combined Immunodeficiency (SCID). Release
Biotech News
@FierceBiotech: Amgen vet reveals stealth startup Flexus, backed by $38M from Kleiner Perkins, Celgene. News | Follow @FierceBiotech
@JohnCFierce: Auspex's Huntington's drug hits the mark in Phase III. Report | Follow @JohnCFierce
@DamianFierce: SV wealthbro Sean Parker pledges $24M to allergy research. Release | Still no word on his last effort. More | Follow @DamianFierce
> Playing a hot hand, Juno ups the ante on a $200M-plus IPO. News
> J&J rents Halozyme's R&D technology for up to $581M. Article
> Neovacs blasted after lead therapy flops in PhIIb for rheumatoid arthritis. Report
Pharma News
@FiercePharma: Speaking of special reports, here's our newest: The top 10 patent expirations of 2015. Feature | Follow @FiercePharma
@EricPFierce: ICYMI: Third round of cuts slated for Novartis US Diovan plant. Total reaches 133 with 394 more gone by 2016. More | Follow @EricPFierce
@CarlyHFierce: Happy Hanukkah, #Pharma... here's a list of next year's biggest patent expirations. Article | Follow @CarlyHFierce
> Novartis sues Cipla for ignoring its COPD drug patents. More
> Gilead chief racks up best-CEO laurels for Sovaldi-fueled 2014. Report
> Mylan, Actavis prevail in Celebrex exclusivity fight, pushing Teva aside. Story
> Belgium's UCB calls it quits on $1.53B sale of U.S. generic drug unit. Article
Drug Delivery News
> Study: Patients don't know how to use drug delivery devices. More
> Sanofi's newly approved intradermal quadrivalent Fluzone forgoes the shot. Item
> Molecular 'hats' disguise peptides until activated with UV light at a target. Article
> MIT spinoff Microchips finishes development of its birth control, osteoporosis implant. Story
> RNAi specialist Alnylam to focus on three therapeutic areas. Report
Diagnostics News
> Roche expands use of next-gen blood tests for organ and tissue screening. Report
> FDA approves diagnostic to spot blood cancer-causing virus. Story
> Ortho-Clinical Diagnostics launches Astute Medical's acute kidney injury test in U.S. hospitals. Item
> Ariosa Diagnostics nabs expanded national coverage for noninvasive prenatal test. Article
> Roche scoops up AvanSci Bio tissue dissection technology to bolster molecular Dx offerings. More
Pharma Marketing News
> Point-of-care marketing could shoot past DTC as pharma's latest trend. Report
> Marketing lesson from Actavis' Namenda ruling: For a hard switch, keep your mouths shut. More
> Actavis revs up new commercial team for post-Allergan-merger sales race. Story
> More CEO watchers put Gilead's Martin on their 'best of 2014' lists. Item
> Sanofi, Regeneron lay groundwork for PCSK9 rollout with Cholesterol Counts campaign. Article